Hyderabad: Good news for aging people sufferingÂ from osteoporosis! Ranbaxy Laboratories on Thursday launched recombinant human parathyroid hormone â€˜Bonista- Teriparatide' injection for the treatment of the disease, in collaboration with Virchow Biotech.
According to the company, the product has been indigenously researched at Virchow in Hyderabad and developed in association with the Department of Science and Technology in India.
Commenting on the launch of the product, Ranbaxy Senior VP and Regional Director (AsiaÂ and CIS) Sanjeev I Dani said that with growing longevity, Osteoporosis a condition characterised by loss of bone mass, would gain increased attention.
Dani claimed that Bonista is a quality bio-generic therapeutic options to doctors and an affordable and efficacious product to patients.
According to the company, with the life span of an average Indian going up,Â the country is witnessing anÂ increase in the number ofÂ osteoporosis cases; with an estimated 50 per cent Indian women having osteoporosis, the actual numberÂ translates to over 30 million.
Experts suggests that one of the reasons could be that the majority of Indians have low vitamin D status and are on low dietary calcium which makes them prone to bone diseases.